Drug Trial Radar · NCT06241183
Famotidine and Antacids for Treatment of Dyspepsia
Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 9, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Stony Brook UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Conditions
- Dyspepsia
- GERD
- Acid Reflux
Interventions
Intravenous FamotidineDrug
Patients in this group will receive 20mg IV Famotidine.
Oral Maalox/ MylantaDrug
Patients in this group will receive 30 ml Maalox/ Mylanta.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Verbal Numerical Pain ScoreTime frame: at 1 hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.